This study aims to explore the relationship between sarcopenia, fatigue, and orthostatic intolerance in older adults. It will be conducted among geriatric patients attending Ain Shams University Hospitals.
Participants aged 65 years and older will be divided into two groups: those with sarcopenia, diagnosed according to the European Working Group on Sarcopenia in Older People 2, and age- and sex-matched controls without sarcopenia. The study will compare levels of fatigue and the presence of orthostatic intolerance between the two groups.
The findings are expected to improve understanding of how sarcopenia is associated with fatigue and orthostatic symptoms in the elderly population, which may help guide better clinical assessment and management.
Eligibility
Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Patients (males or females) aged 65 or above years old.
* Participants who are willing to participate in the study.
Exclusion Criteria:
* Patients who are not willing to participate in the study.
* patients with end organ damage (CHF NYHA III/IV), end-stage renal disease, Liver cell failure, respiratory failure.
* Patients with arrhythmia or using pacemakers
* patients diagnosed with parkinsonism, Diabetes mellitus, or peripheral neuropathy.
* Active infections or inflammatory conditions (e.g., sepsis, rheumatoid flare-up)
* Patient with acute stroke, Critically ill patients, Terminal illness, Bedridden or completely immobile patients,
* Medications Influencing Fatigue/OI: High-dose opioids, sedatives, or drugs causing significant orthostatic hypotension (e.g., alpha-blockers, diuretics without stable control)
Primary outcome measure(s)
Fatigue severity measured by Fatigue Severity Scale (FSS) — Baseline Difference in Fatigue Severity Scale (FSS) total score between geriatric patients with sarcopenia (defined according to European Working Group on Sarcopenia in Older People 2 criteria) and those without sarcopenia.
Unit of Measure:
FSS total score (range: 1-7)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.